当前位置: X-MOL 学术Cancer Discov. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Gemtuzumab Ozogamicin Makes a Comeback
Cancer Discovery ( IF 29.7 ) Pub Date : 2017-09-20 , DOI: 10.1158/2159-8290.cd-nb2017-132
American Association for Cancer Research

After being pulled from the market 7 years ago, gemtuzumab ozogamicin has been reapproved by the FDA, this time for adults newly diagnosed with acute myeloid leukemia, as well as patients 2 years of age and older with relapsed/refractory disease. The CD33-targeting antibody–drug conjugate can be given as a single agent or in combination with chemotherapy.



中文翻译:

Gemtuzumab Ozogamicin卷土重来

吉妥单抗ozogamicin在7年前被撤出市场后,已获得FDA的重新批准,这次是针对新诊断为急性髓性白血病的成年人以及2岁及以上复发/难治性疾病的患者。靶向CD33的抗体-药物偶联物可以单药或与化学疗法联用。

更新日期:2017-09-20
down
wechat
bug